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In the current work, a sustained drug delivery system of flutamide (FLT) was developed using 
Poly(D,L‑lactide‑co‑glycolide) (PLGA) decorated bypoly(ethylene glycol) (PEG) grafted prazosin 
(PLGA‑PEG‑Praz) as a targeting moiety. In a multi‑step reaction, PLGA was linked to PEG and prazosin. 
The structure of the synthesized polymers was confirmed by FTIR and 1H-NMR. Flutamide-loaded 
nanoparticles were prepared by quasi‑emulsion solvent diffusion technique. The nanoparticles were 
evaluated for size, zeta potential, polydispersity index, drug crystallinity, loading efficiency, and release 
properties. Also, the physicochemical properties of the nanoparticles were analyzed using Scanning 
Electron Microscopy (SEM), Differential Scanning Calorimetry, and Powder X‑Ray Diffractometry 
(XRD). The particle size of nanoparticles was ranged between 191 and 249 nm. Loading efficiency of 
nanoparticles was about 43%‑69%. Results showed a steady release rate for nanoparticles compared to 
that of a pure drug powder. SEM characterization confirmed that particles were in nanosize range. DSC 
and XRPD results verified a decrease in drug crystallinity in the prepared formulations. In conclusion, 
the results of this study showed that PLGA‑PEG‑Praz nanoparticles could be a good choice to improve 
the physicochemical properties of the drug and these formulations can increase Flutamide efficacy.
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INTRODUCTION
Prostate cancer is one of the most common cancers 
in adult males in the United State (Alldredge et al., 2013; 
Anitha et al., 2013). Treatment of advanced prostate 
cancer relies mainly on non‑specific therapies such as 
chemotherapy and ionizing radiation, which have a low 
efficacy and are highly toxic to normal tissues (Xu et al., 
2013). 
The function and proliferation of prostate cells are 
physiologically dependent on androgens (Heidenreich 
et al., 2009). Flutamide (FLT) is a potent non‑steroidal 
anti-androgen drug clinically used for the treatment of 
advanced prostate cancer (Anitha et al., 2013; Samy 
2012). This drug reduces testosterone only on frequent 
administration because it undergoes extensive first‑pass 
metabolism, and its metabolites are less active (Anitha et 
al., 2013; Samy, 2012). In addition, the therapeutic effect 
of the FLT is hampered by a low bioavailability due to 
its low water solubility (9.45mg/L) and poor wettability 
(Anitha et al., 2013; Samy, 2012; Zuo et al., 2000). 
Moreover, high doses of FLT cause hepatotoxicity (Adlin, 
Gowthamarajan, Somashekhara, 2009).
Application of polymer‑based nanoparticles (NPs) 
using biodegradable polymers for drug delivery is widely 
expected to change the landscape of the pharmaceutical 
and biotechnology industries in the near future (Farokhzad, 
Langer 2009; van Vlerken, Vyas, Amiji, 2007). Polymeric 
NPs have been shown to improve drug efficacy through 
sustained delivery over a long time period or drug delivery 
with a minimization of side effects (Singh, Lillard, 2009).
Poly(D,L‑lactide‑co‑glycolide) (PLGA) belongs 
to the best‑known class of biodegradable polymers 
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for sustained and controlled release. This polymer is a 
biodegradable and biocompatible and is hydrolytically 
degraded into the non-toxic monomers, lactic acid, and 
glycolic acid. PLGA polymers are already approved by the 
US Food and Drug Administration (FDA). Besides, several 
micro/nanoformulations of PLGA have been adapted to 
various types of drugs; e.g., hydrophilic and hydrophobic 
molecules, small molecules, and macromolecules 
(Valizadeh et al., 2012; Danhier et al., 2012).
Malignant tumors can be treated with the PLGA 
NPs through passive targeting. Passive targeting takes 
advantage of nanoparticles’ size and exploits the unique 
anatomical and pathological abnormalities of the tumor 
vasculature; i.e., enhanced permeability and retention 
(EPR) effect. While NPs can passively target tumors 
through the EPR effect, the main challenge of using the 
NPs for drug delivery to tumors is their clearance by the 
mononuclear phagocytic system from the bloodstream 
(van Vlerken et al., 2007; Mohanraj, Chen, 2006). The 
recognition of NPs by reticuloendothelial system (RES) 
cells can be limited by imparting stealth shielding on the 
NP surface. Poly(ethylene glycol)(PEG) modification 
known as PEGylation has emerged as a common strategy 
to ensure such stealth-shielding and long circulation of 
the NPs (Jokerst et al., 2011). PEG is a coiled polymer of 
repeating ethylene ether units that provides hydrophilic 
and neutral chains at the particle surface and repel plasma 
proteins (van Vlerken et al., 2007; Mohanraj, Chen, 2006). 
PEG coatings facilitate a stealth-NP formulation, which 
allows escaping from RES cells and, therefore, increases 
the NP’s systemic circulation time (van Vlerken et al., 
2007; Liu et al., 2010). 
In general, limitations of conventional treatments 
are associated with the non‑specific targeting of the 
therapeutic modalities (Wadajkar et al., 2013). Active 
targeting can be realized by “decorating” the NP surface 
with specific ligands (Zhang, Lee, Feng, 2007). Extensive 
studies have been performed to achieve the active targeting 
of NPs in order to deliver drugs to the target cells, based 
on ligand‑receptor or antigen‑antibody interactions 
(Mohanraj, Chen, 2006; Pan, Feng, 2009). The receptor‑
ligand complex can be progressed to internalization via 
endocytosis, which may promote the cytosolic delivery 
of drugs. Targeted NPs demonstrated considerable 
advantages versus non-targeted NPs in achieving lower 
levels of side effects and a higher therapeutic efficiency 
(Ebrahimnejad et al., 2011; Pan, Feng, 2008; Zhao, Yung, 
2008).
Prazosin is an α1‑adrenoceptor antagonist used as 
a first‑line medical treatment of prostatic hyperplasia 
related to lower urinary tract symptoms. It binds to α1-
adrenoceptors on smooth muscle cells of the prostate and 
bladder tissues and consequently reduces muscle tone 
and relieves bladder obstruction. Furthermore, several 
lines of evidence suggest that prazosin induces apoptosis 
in prostate cancer and inhibits angiogenesis (Lin et al., 
2007; Liao et al., 2011). Therefore, decoration of prostatic 
anticancer drug‑loaded NPs by prazosin not only provides 
receptor‑mediated endocytosis and active targeting 
but also improves system efficacy through its synergic 
anticancer effects.
This study was conducted to describe the preparation 
of FLT‑loaded PLGA and PLGA‑PEG‑prazosin (PLGA‑
PEG‑Praz) NPs to sustain the release of FLT and improve 
the physicochemical properties of the drug. Moreover, 
the relative cytotoxic potencies of FLT and FLT‑loaded 
PLGA‑PEG‑Praz are evaluated in PC‑3 prostate cancer 
cell line.
MATERIAL AND METHODS
Material
Poly(D,L‑lactide‑co‑glycolide) (PLGA) (50:50 
D,L‑lactide:glycolide) with terminal carboxylate groups 
and average molecular weight of 44,000 g/mol(Resomer 
RG 502) was obtained from Purac,The Nederland. Diethyl 
ether, dichloromethane (DCM), polyvinyl alcohol (PVA, 
Mw 88,000) and poly(ethylen glycol) (PEG, Mw 6,000) were 
purchased from Merck,Germany.Dimethylaminopyridine 
(DMAP), dimethyl sulfoxide (DMSO), FLT, prazosin, 
dimethylaminopropylcarbodi imide (EDC) and 
N‑hydroxysuccinimide (NHS) were all purchased from 
Sigma‑Aldrich, USA. N,N’‑diisopropylcarbodiimide 
(DIPC) was obtained from Fluka, Japan. PEG was dried 
azeotropically with toluene, and dichloromethane was 
dried over CaH2 and stored over molecular sieve (4 Å). 
Other compounds were used without any purification.
Methods
Synthesis of the PLGA–PEG–Praz conjugate
The synthesis of Prazosinconjugates followed 
a three‑step reaction (Figure 1): synthesis of PEG‑
COOH, conjugation of prazosin to PEG (Praz–PEG) and 
conjugation ofPLGA with Praz–PEG to form PLGA‑PEG‑
Praz. (Figure 1)
• Synthesis of PEG‑COOH
PEG‑COOH was prepared according to the method 
developed by SijianHou et al (2007) (Hou, McCauley 
and Ma 2007), with minor modifications. Briefly, dried 
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PEG, succinic anhydride, N,N’‑diisopropylcarbodiimide 
(DIPC), and 4‑dimethylaminopyridine (DMAP) at molar 
ratios of 1,1.4,1.4 and 1.2 were used respectively. Succinic 
anhydride andDMAP were completely dissolved in 15 mL 
of anhydrous DCM and kept at 0 °C for 30 min. PEG 
and DIPC were mixed in 15 mL of DCM and transferred 
slowly into the succinic anhydride solution using a 
syringe underthe nitrogen atmosphere. The solution was 
stirred at 0 °C for 2 h and the reaction was continued in 
DCMunder nitrogen gas at room temperature for 48 h. At 
the end of reaction time, the insoluble solid was filtered 
off. The PEG‑COOH was precipitated in cold diethyl 
ether. The precipitates were again dissolved in DCM and 
re‑precipitated in cold diethyl ether. The precipitates were 
washed by diethyl ether for several times and dried under 
vacuum at room temperature overnight.
PEG‑COOH: 1H NMR (DMSO, 400 MHz) δ (ppm): 
2.42‑2.45 (4H, d), 3.51 (4H, a), 3.58‑3.6 (2H, b), 4.1‑4.
• Synthesis of Praz‑PEG
The amide reaction was carried out using the 
similar methods reported previously (Hou, McCauley, 
Ma, 2007), with minor modifications.PEG‑COOH was 
reacted with EDC and N‑hydroxysuccinimide (NHS) in 
anhydrous DMSO at stoichiometric molar ratio of 1,2 
and 2, respectively for 6 h at room temperature. Then 
the excess amount of prazosin dissolved in DMSO and 
transferredslowly into the activated PEG solution using 
a syringe under the nitrogen atmosphere. The reaction 
was continued under nitrogen gas protection and stirred 
at room temperaturefor 72 h.
Final solution was added to a dialysis membrane 
tube (Mwcut‑off: 3500, orange). The membrane was 
sealed and suspended in 2L of deionized water and the 
solution was stirred gentlyat room temperature.After 2 
h the deionized water was replaced by a fresh batch of 
deionized water and the process was repeated four times. 
The resultant product was obtained by freeze‑drying.
Praz‑PEG:1H NMR (DMSO, 400 MHz) δ (ppm): 
2.42‑2.46 (4H, d), 3.58‑3.6 (2H, b), 3.51 (4H, a), 3.79,3.84 
(6H, OCH3), 4.11‑4.12 (2H, c), 6.64‑6.66 (1H, H4‑Furan), 
6.75 (1H, H5‑Quinazoline), 7.03‑7.04 (1H, H5‑Furan), 
7.0435 (1H, H8‑Quinazoline), 7.87‑7.86 (1H, H3‑Furan).IR 
(KBr, cm-1): 3448 (O‑H, N‑H stretch), 2885 (C‑H, stretch), 
1735 (C=O, stretch, ester), 1635 (C=O, stretch, amide), 
1597 (C=C, stretch), 1107 (C‑O‑C, stretch), 1060 (C‑O, 
stretch, alcohol).
• Synthesis of PLGA‑PEG‑Praz
PLGA‑PEG‑Praz was synthesized by reacting 
PEG‑Praz,PLGA, N,N’‑diisopropylcarbodiimide (DIPC), 
and 4‑dimethylaminopyridine (DMAP) at molar ratio 
of 2,1, 2, and 2respectively. PLGA was dissolved in 
30 mL of anhydrous DCM, and DIPC,DMAP and PEG‑
Prazwereaddedto this solution at 0 °C.
The solution was stirred at 0 °C for 2 h,and then 
the ice bath was taken out to warm solution to room 
temperature.
The reaction was continued in dichloromethane 
under nitrogen gas at room temperaturefor 48 h. At the end 
of reaction time, the insoluble solid was filtered off. The 
PLGA‑PEG‑Praz was precipitated in cold diethyl ether. The 
precipitates were dissolved in DCM and re‑precipitatedin 
cold diethyl ether. The precipitates were washed by diethyl 
ether and deionized water for several times and dried under 
vacuum at room temperature overnight. 
PLGA‑PEG‑Praz:1H NMR (DMSO, 400 MHz) δ 
(ppm): 3.58‑3.6 (2H, b), 3.51 (4H, a), 4.1‑4.13 (2H, c), 3.86 
(OCH3), 1.47‑1.48 (3H, ((OCH(CH3)C(O)CH2C(O))n), 
4.92 (2H, ((OCH(CH3)C(O)CH2C(O))n), 5.18‑5.27 (1H, 
((OCH(CH3)C(O)CH2C(O))n).IR (KBr, cm-1): 3245‑3510 
(O‑H,N‑H, stretch), 2854‑2993 (C‑H, stretch), 1751 (C=O, 
stretch, ester), 1654 (C=O, stretch, ester), 1631(C=O, 
stretch, amide), 1543 (C=C, stretch), 1107 (C‑O‑C, 
stretch), 1060 (C‑O, stretch, alcohol).
FIGURE 1 ‑ Chemical conjugation of PLGA with PEG‑Praz.
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Preparation of nanoparticles
NPs with 1:2, 1:3 and 1:5 ratios of the drug to PLGA 
and 1:3 ratio of the drug to targeted PLGA were prepared 
by nano‑precipitation according to the modified quasi 
emulsion solvent diffusion technique (Lee, Na, Bae, 2003).
FLT with PLGA or PLGA‑PEG‑Praz powder were 
co‑dissolved in internal phase (2.5 mL DMSO) at room 
temperature (25 °C). Typically, different ratios of drug 
and polymer, with the total amount of 100 mg, were co‑
dissolved in DMSO. The resulting organic solution was 
injected at the constant rate of 0.5 mL/min in aqueous phase 
(40 mL) containing PVA (1% w/v), as a stabilizing agent.
The process was carried out under homogenization 
for 5 min using the T18 basic homogenizer (IKA, Brasil). 
The agitation speed was 12000 rpm in an ice‑water bath. 
DMSO was eliminated at the room temperature under 
stirring for 12 h. The final nano‑suspension was centrifuged 
(Avanti TM J‑25, Beckman, USA) at 14000 rpm for 20 min 
and the precipitated NPs were washed twice with water, 
using the previously described centrifugation approach. 
Then NPs were freeze‑dried. 
Structural characterization of polymeric conjugates
Infrared (IR) and 1H NMR spectra were prepared 
in order to confirm the chemical structure of polymers. 
Infrared spectra were obtained using a Shimadzo‑
Irprestige‑21spectrometer. The samples were pressed 
into KBr pellets for analysis.1H NMR measurements of 
samples in DMSO were performed on a 400‑MHz proton 
NMR spectrometer (AC‑400, BrukerBiospin, Germany), 
Chemical shifts were expressed asparts per million, ppm.
Evaluation of the particle size, zeta potential and 
morphology of nanoparticles
The particle size and size distribution of the prepared 
NPs were determined via the laser diffraction particle size 
analyzer (Zetasizer, Malvern, UK). To assess the size of 
NPs, the dried powder samples were suspended in distilled 
water and slightly sonicated (Tecna3, Tecno‑Gaz, Italy) at 
70% amplitude for 30 sec before measurement. The mean 
diameter and size distribution of the resulted homogeneous 
suspension were assessed, subsequently. 
The particle surface charge was quantified as zeta 
potential (ζ potential) using a Zetasizer. Measurements 
were performed in distilled water.
The morphology of the NPs was investigated 
by scanning electronmicroscopy (SEM, LEO440i, 
LeoElectronMicroscopyLtd., Cambridge, UK) at an 
accelerating voltage of 20 kV. Prior to examination, 
samples were prepared on aluminum stubs and coated with 
gold under argon atmosphere by a sputter coater.
Differential scanning calorimetry (DSC)
Accurately weighed samples, equivalent to 3 mg of 
FLT, were placed into the sealed standard aluminum pans 
with lids. Afterward, the physical status of the FLT inside 
the NPs was ascertained using the differential scanning 
calorimetry thermogram analysis, (DSC60, Shimadzu, 
Japan). 
Thermal behavior of the samples was investigated at 
a scanning rate of 40 °C/min covering temperature range 
of 20-240 °C.
The aluminum oxide and indium powders were 
employed as referenceand standard, respectively. DSC 
analysis of pure FLT, PLGA and PLGA‑PEG‑Praz was 
performed to identify the drug melting point peakand 
polymer glass transition temperature (Tg). 
X-ray powder diffraction
The X‑ray powder diffraction (PXRD), pattern of 
the drug, PLGA, PLGA‑PEG‑Praz, NPs and physical 
mixture in the 1:3 drug to polymer ratio were recorded 
using an automated X‑ray diffractometer (Siemens‑
850,Germany). Cross‑section of the samples were taken 
and held in place on a quartz plate for exposure to Cu Kα 
radiation of wavelength 1.5406 Å. Diffractograms were 
run at scanning rate of 0.06° cm-1, over the range of 5‑60° 
and with sampling intervals of 0.02.
Encapsulation efficiency
FLT content in the NPs was determined by UV‑V 
is spectrophotometry (Mohammadi et al., 2011).Three 
samples from each preparation, equivalent to 6 mg drug 
were chosen randomLy and were dissolved in DMSO. 
After appropriate dilution, the absorbance was measured 
using UV spectrophotometer at 315 nm using DMSO 
containing polymer as a blank.
Encapsulation efficiency was calculated by the 
following equation:
where W is the weight of drug entrapped in NPs and Wo 
is the weight of the initial feeding drug.
Invitro drug release
The in vitro drug release study was carried out using 
dialysis method in sink conditions (Elgindy et al., 2011). A 
known weight of NPs (equivalent to 5 mg drug) was placed 
in a cellulosic membrane tube (Mw cutoff of 3500) and was 
added to 75.75 mL PBS (pH 7.4) containing 0.2% (w/v) 
tween 80. The container transferred into the shaker incubator 
at 37 °C with continuous orbital mixing (100 rpm). At 
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specified times intervals (0.5,1,2,3,4,6,8,10,12,24,26, and 
28 h), 0.4 mL samples were removed and filtered through a 
0.45µmsiringfilter. After each sampling, an equal volume 
of pre‑warmed fresh dissolution media was replaced. 
The drug concentrations in the samples were analyzed at 
315 nm using a spectrophotometer (Shimadzu, Japan). 
The cumulative amount of the released FLT was calculated 
considering the replaced volume of the dissolution medium 
and the cumulative percentage of the released FLT was 
plotted versus time. The mean calculated values were 
obtained from Three replicates.
MTT cell proliferation assay
PC‑3 (human prostate cell carcinoma) was obtained 
from Pasteur Institute (Tehran, Iran). The cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM‑F12) 
with 10% (v/v) fetal bovine serum, 100 UmL−1 penicillin, 
and 100 mgmL−1 streptomycin. Cell proliferation was 
determined using the 3‑[4,5‑dimethylthiazol‑2‑yl)‑2,5‑
diphenyltetrazoliumbromide] (MTT) assay. Briefly, the cells 
were plated in 96‑well cell culture plates at a cell density of 
15×104 cells per well. After 48 h the medium was replaced 
with fresh medium containing increasing concentrations 
of the FLT and FLT and FLT –loaded PLGA‑PEG‑Praz. 
A negative control of untreated cells was also included. 
The cells were incubated for a further 48 h, after which a 
0.5 mg/mL MTT solution (10 μL per well) was added 
and the cells incubated for an additional 4 h. Then, the 
medium was removed, and the purple formazan crystals 
were dissolved in DMSO (200 µL/ well). Absorbance was 
determined on an ELISA plate reader (Biotek, H1 M) with 
a test wave length of 570 nm and a reference wavelength of 
630 nm to obtain sample signal (OD570–OD630).
RESULTS AND DISCUSSION
Characterization of the synthesized polymers
The structure of the synthesized polymers was 
confirmed by FTIR and 1HNMR. FTIR spectra of the 
Prazosin, PLGA, PEG‑Succ, PEG‑Praz, and PLGA‑PEG‑
Praz are shown in Figure 2. As can be observed from the 
PEG‑Succinic acid spectrum, peaks at 2,884 and 2,993 cm−1 
correspond to C‑H stretching. The absorption band at 
1,107 cm−1 is indexed to the characteristic C‑O‑C stretching 
vibrations of the repeated OCH2CH2units of PEG. The 
appearance of the absorption band at 1,735 cm−1 is indexed 
to the C=O stretching vibrations of the carbonyl‑ester, which 
indicates the successful synthesis of PEG-Succinic acid. In 
the PEG‑Prazspectrum, the absorption bands at 1,635 and 
671.23 cm−1 are indexed to the amide C=O stretching of 
Prazosin. The absorption band at 1,597 cm−1 is related to the 
C=C stretching of the aromatic ring in prazosin.
Finally, the PLGA‑PEG‑Praz spectrum shows 
an absorption band at 1,107 cm−1 is indexed to the 
characteristic C‑O‑C stretching vibrations of the repeated 
OCH2CH2 units of PEG. The absorption band at 1,735cm−1 
is indexed to the C=O stretching vibrations of the carbonyl 
ester and the absorption bands at 1,635 cm−1 are indexed to 
amide C=O stretching. A sharp peak indexed to the C=O 
stretching vibrations of the ester carbonyl group in PLGA 
appeared at 1,751 cm−1.
1H‑NMR spectra are shown in Figure 3 to further 
confirm the formation of the synthesized polymers. The 
sharp single peak at 3.51 ppm in PEG spectrum is indexed 
to the methylene protons of PEG unit home sequences. 
The chemical shifts at δ = 2.42‑2.46 ppm are indexed to 
succinate moieties of PEG‑Succ (Figure 3C). The peaks 
at 3.79, 3.84, and 3.86 ppm are indexed to the protons on 
OCH3 groups, and the chemical shifts at 6.64–6.66, 6.75, 
7.03, 7.04, 7.86, and 7.87 ppm (Figure 3E) are ascribed 
to other protons in Prazosin, which confirm a successful 
conjugation (Zhao et al., 2010).
Hydrogen atoms in the methylene group of the 
lactic acid unit of the PLGA copolymer resonated at 
5.18‑5.27 ppm, whereas those of the methylene group of 
the glycolic acid unit appeared at 4.92 ppm. Here, the CH 
peak at approximately 1.48 ppm confirms the presence of 
PLGA (Figure 3E) (Mahalwar et al., 2012).
Loading study
Loading results revealed a maximum FLT loading 
of about 69.1% that increased linearly with the increase 
in PLGA amount. This observation may be attributed 
to the higher viscosity of the internal organic phase at 
higher PLGA ratios, which in turn would decrease the 
diffusion coefficient of the drug. Furthermore, at higher 
polymer ratios, the extent of drug loss during the washing 
procedure was reduced (Koopaei et al., 2012). Compared 
to PLGA NPs, PLGA‑PEG‑PrazNPs had a higher loading 
efficiency, which could be related to a higher viscosity 
(Cun et al., 2010) and to the NPs’ hydrophilic shells, which 
increase the affinity of FLT to its hydrophobic core and 
consequently increases the loading efficiency.
Physicochemical characterizations
Characterization of nanoparticles: size, morphology, 
and zeta potential
Submicron particles ranging from 191.8 ± 23.4 to 
249.13 ± 33.6 nm with a narrow size range and a relatively 
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monodisperse distribution were achieved using a modified 
quasi‑emulsion solvent diffusion technique (Table I).
The zeta potentials of NPs are shown in Table I. 
Given the neutral charge of FLT, despite an increase in the 
PLGA in NPs, the surface charge remained constant. Zeta 
potential gives an idea about the charge of the particle; 
the higher the zeta potential, the higher the charge on 
the particle surface would be. The surface charge on 
the particles could control the particles stability of the 
nanoparticulate formulation through strong electrostatic 
repulsion of particles with each other. The nanoparticles 
demonstrated negative zeta potential values (–1.98 mV 
to –1.66 mV), which can be attributed to the presence 
of the ionized carboxyl group of PLGA on the particles’ 
surface. Interestingly, pure PLGA showed a much lower 
zeta potential (–30 mV to –50 mV), suggesting that drug 
adsorbs on the surface of the nanoparticles. Also, the 
values of the zeta potential of drug PLGA‑PEG‑Praz were 
obviously affected by the presence of PEG chains. 
SEM experiments revealed a spherical morphology 
and a relatively smooth surface for the resultant NPs 
(Figure 4, Table I).
PowderX-ray diffraction (PXRD) and differential 
scanning calorimetry (DSC)
PXRD and DSC experiments were carried out 
to assess the crystallinity properties and scrutinize any 
possible interactions between the drug and polymer in 
the prepared NPs. 
DSC thermograms of intact FLT, PLGA, physical 
mixtures (1:3 ratio), and NPs are shown in Figure 5. 
DSC is one of the most common methods to assess the 
physicochemical interactions between drugs and polymers 
in a given formulation. Intact FLT powder showed an 
endothermic peak corresponding to its melting point at 
119.92 °C (Figure 5). There was a sharp drop in the FLT 
FIGURE 2 - FT‑IR of the prazosin (A), PLGA (B), PEG (C), 
PEG‑succinic acid (D), PEG‑Praz(E), and PLGA‑PEG‑Praz (F).
FIGURE 3 - 1HNMR of the prazosin (A), PEG (B), PEG‑succinic 
acid (C), PLGA (D), PEG‑Praz (E).
FIGURE 4 - SEM image of flutamide nanoarticles.
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melting point and enthalpy of fusion in the PLGA NP 
thermograms at 1:2, 1:3, and 1:5 drug to polymer ratios 
(Figure 5A) and PLGA‑PEG‑Praz NPs at a 1:3 ratio 
(Figure 5B), suggesting that the formulation process 
induced an amorphous phase in the samples. The glass‑
transition temperature of PLGA was found to be 56.01 °C.
XRD is frequently used to analyze the degree of 
sample crystallinity. As shown by the XRD patterns 
(Figure 6), intact FLT had distinct peaks at 2θs of 8°, 12°, 
17°, 19°, 3.8°, 24°, 28.5°, and 32°, corresponding to the 
crystal form of FLT. This observation was confirmed by 
the DSC melting endotherm at 119.92 °C. There was no 
clear peak in the XRD pattern for the amorphous polymer. 
The XRD pattern of the physical mixtures indicated that 
the intensities of typical peaks for the intact drug were 
lowered due to a dilution effect without a qualitative 
disparity in drug diffractogram. NPs were characterized 
by the absence of distinct (or unclear) diffraction peaks, 
TABLE I - Polydispersity (±SD), mean (±SD) particle diameter, zeta potential, and encapsulation efficiency (±SD)of the various 
nanoparticles
Formulations Polydispersity Mean particle size (nm)
Zeta potential 
(Mv)
Encapsulation 
efficiency (%)
1:3Drug: PLGA-PEG-Praz 0.260 ± 0.030 194.60±37.0 -1.82 69.1% ± 4.7
1:2Drug:PLGA 0.180 ± 0.014 191.80 ± 23.4 -1.80 43.0% ± 4.0
1:3Drug:PLGA 0.200 ± 0.012 219.70 ± 6.2 -1.66 50.0%  ± 5.0
1:5 Drug:PLGA 0.162 ± 0.050 249.13± 33.6 -1.98 64.0% ± 4.5
FIGURE 5 - DSC curve of the intact flutamide powder, 
PLGA, PLGA‑PEG‑Parz, physical mixture of drug: PLGA 
1:3, nanoparticles of drug: PLGA 1:3, and PLGA‑PEG‑Parz 
nanoparticles.
FIGURE 6 - Powder X‑ray diffraction of intact flutamide powder, 
physical mixtures, flutamide‑loaded nanoparticles.
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signifying a drug amorphization or its dissolution in the 
amorphous carrier (Figure 6). XRD results were consistent 
with the findings obtained from DSC analysis. Concisely, 
the DSC and XRD studies confirmed a decrease in drug 
crystallinity in the NPs (Figure 5 and Figure 6)
In vitro release
FLT release profiles from intact drug powder and the 
formulated drug‑polymer NPs are shown in Figure 7. As 
can be seen, the intact drug powder had a lower dissolution 
rate, which could be due to poor wettability and the low 
aqueous solubility of the drug.
All the NPs demonstrated a steady and uniform drug 
release profile in comparison with the intact drug, which 
may be because of the diffusion of the drug localized 
in the PLGA core of the NPs. There were no distinct 
differences between PLGA‑NPs prepared at different 
ratios, demonstrating that the release rate was not affected 
by the increase in PLGA in the NPs.
The release profiles from PLGA‑PEG‑Praz NPs 
have more dissolution rate in comparison with other 
formulations, probably due to the presence of the 
soluble polymer (PEG) in the matrix body of these NPs, 
which in turn increases the water penetration and hence 
dissolution and diffusion. Similar observations were 
reported by previous studies on bovine serum albumin‑ 
and cyclosporin‑loaded PLGA‑PEG NPs (Li et al., 
2001; Tang et al., 2012). The release data of nanoparticle 
formulations were fitted into 11 release mathematical 
models including zero‑order, first‑order, square root of 
mass, three seconds root of mass, Higuchi square root, 
Hixson‑Crowell cube root, Peppas, Peppas‑Sahlin, 
linear probability, Logarithmic probability, and Weibull 
model. The predicted error values between the observed 
and calculated release data as well as the coefficient 
of determination (R2) for different formulations were 
calculated. For the PLGA nanoparticles with a drug to 
polymer ratios 1:2 and 1:3, the Logarithmic probability 
model was the best‑fitted kinetic model with the predicted 
error range of 5.3%‑6.2%. The release mechanism might 
be due to the erosion and degradation of the nanoparticles. 
For the PLGA nanoparticles with a drug to polymer ratio 
1:5 and the PLGA‑PEG‑Praz nanoparticles with a drug to 
polymer ratio 1:3, the Weibull model was the best‑fitted 
kinetic model with the predicted error range of 4.2% and 
4.3% (Figure 7).
Relative cytotoxic potency
The viability of PC-3 cells was evaluated after 
48 h exposure to different concentrations of the FLT 
and FLT‑loaded PLGA‑PEG‑Praz using MTT method 
as described in the material and methods. As shown in 
Figure 8, the FLT was not able to induce cytotoxicity in 
a PC‑3 cell line, up to a concentration of 100 µM. FLT‑
loaded PLGA‑PEG‑Praz possessed a good inhibitory 
effect against PC‑3, human cancer prostate cell. Exposure 
toFLT‑loaded PLGA‑PEG‑Praz for 48 h resulted in a 
concentration‑dependent decrease in cell viability, with 
approximate IC50 of 71.6±4.3 µM. It can be concluded 
that this formulation can increase FLT cytotoxic effect 
in human prostate cancer cells. However, more details 
and methods must be employed to explore the molecular 
mechanism that mediated increase cytotoxic effect 
of FLT‑loaded PLGA‑PEG‑Praz in PC‑3 cell line. 
Moreover, further studies are underway in our laboratory 
to evaluate the cytotoxic effect of FLT‑loaded PLGA‑
PEG‑Praz in other human prostate cancer cells like 
LNCap and DU‑145 (Figure 8).
CONCLUSION
The present study showed that PLGA‑PEG‑Praz 
could be a useful nanocarrier for FLT. PLGA‑PEG‑Praz 
was synthesized successfully by a multi‑step reaction. 
Nanoparticles were prepared by quasi‑emulsion solvent 
diffusion technique. As a result, nanoparticles with 
the efficient loading of FLT were obtained. FLT was 
in the amorphous form in the nanoparticles. Prazosin‑
decorated nanoparticles had higher loading efficacy 
and faster release compared to the PLGA nanoparticles. 
These phenomena altogether make FLT loaded NPs as a 
potential drug delivery system for treatment of prostate 
cancer.
FIGURE 7 ‑ Dissolution profiles of intact flutamide powder and 
flutamide‑loaded nanoparticles with drug to PLGA ratio of 1:2, 
1:3, 1:5, and drug to PLGA‑PEG‑Praz ratio of 1:3.
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